Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
06/2010
06/10/2010US20100144744 Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
06/10/2010US20100144741 Ethanolamine derivatives useful as bace inhibitors
06/10/2010US20100144738 Inhibitors of c-met and uses thereof
06/10/2010US20100144727 Oxazolidine and Morpholine Carboxamide Derivatives as P2X7 Modulators
06/10/2010US20100144723 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione
06/10/2010US20100144721 Inhibitors of c-met and uses thereof
06/10/2010US20100144715 Substituted Benzodiazepinones, Benzoxazepinones and Benzothiazepinones as Sodium Channel Blockers
06/10/2010US20100144714 Derivatives of imidazo pyrimido and diazepine pyrimidine-dione, and use thereof as a drug
06/10/2010US20100144710 Piperazine and Piperidine MGLUR5 Potentiators
06/10/2010US20100144709 Thiadiazole derivatives for the treatment of neuro-degenerative diseases
06/10/2010US20100144701 Modulators of CB1 Receptors
06/10/2010US20100144700 Heterocyclic-carbonyl-diazabicycloalkanes as modulators of the neuronal nicotinic acetylcholine alpha 4 beta 2, subtype receptor for the treatment of cns related disorders
06/10/2010US20100144681 Compounds for the treatment of alzheimer's disease
06/10/2010US20100144676 Oleyl phosphocholine
06/10/2010US20100144665 Treatment of statin side effects
06/10/2010US20100144653 Fatty acid carbohydrate hybrid molecules as therapeutic agents and methods thereof
06/10/2010US20100144649 Compounds for enzyme inhibition
06/10/2010US20100144648 Compounds for enzyme inhibition
06/10/2010US20100144645 Compositions and methods for enhancing analgesic potency of covalently bound-compounds, attenuating its adverse side effects, and preventing their abuse
06/10/2010US20100144631 Concentrated Protein Preparations of Bone Morphogenetic Proteins and Methods of Use Thereof
06/10/2010US20100144624 Process for the preparation of compositions of at1 receptor antagonist and angiotensin-(1-7)
06/10/2010US20100144594 2-heteroaryl-pyrrolo[3,4-c]pyrrole derivatives and their use as scd inhibitors
06/10/2010US20100143962 Nanoparticulate polycosanol formulations & novel polycosanol combinations
06/10/2010US20100143507 Carboxylic acid inhibitors of histone deacetylase, gaba transaminase and sodium channel
06/10/2010US20100143505 Indanone inhibitors of acetylcholinesterase
06/10/2010US20100143485 Oxycontin controlled release formulations and methods of using same
06/10/2010US20100143483 Pharmaceutical compositions
06/10/2010US20100143475 Transdermal therapeutic system with two-phase release profile
06/10/2010US20100143474 B-carboline for the treatment of neurodegenerative diseases
06/10/2010US20100143469 Pharmaceutical compositions
06/10/2010US20100143465 Pharmaceutical composition
06/10/2010US20100143458 Glutamic acid decarboxylase (gad) based delivery system
06/10/2010US20100143452 Polyphenol containing compositions
06/10/2010US20100143424 Casein nanoparticle
06/10/2010US20100143420 Multi-phasic pharmaceutical formulations of poorly water-soluble drugs for reduced fed/fasted variability and improved oral bioavailability
06/10/2010US20100143396 Method for Preparing a Covalently Cross Linked Oligomer of Amyloid Beta Peptides
06/10/2010US20100143361 Methods for the treatment of a-beta related disorders and compositions therefor
06/10/2010US20100143357 Uses of Mammalian Cytokine; Related Reagents
06/10/2010US20100143355 Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
06/10/2010US20100143349 Humanized anti-rage antibody
06/10/2010US20100143344 Complement inhibition for improved nerve regeneration
06/10/2010US20100143322 Use of inhibitors of n-methyl transferases for the therapy of parkinson's disease
06/10/2010US20100143310 SPINAL NERVE REPAIR PROMOTING THERAPEUTICS CONTAINING GHRELIN OR ITS DERIVATIVES OR SUBSTANCES THAT ACT ON GHS-R1a AS AN ACTIVE INGREDIENT
06/10/2010US20100143290 Monoclonal antibodies to human thymidine kinase to treat cancer
06/10/2010US20100143264 Compositions for aerosolization of highly conductive solutions
06/10/2010US20100143253 Compounds and amyloid probes thereof for therapeutic and imaging uses
06/10/2010US20100143246 Interleukin 17 Receptor-Like Protein
06/10/2010DE102005054610B4 Flupirtin enthaltende Arzneimittelzubereitung mit kontrollierter Wirkstofffreisetzung Flupirtine-containing pharmaceutical composition with controlled drug release
06/10/2010CA2745721A1 Substituted piperidine spiro pyrrolidinone and piperidinones used as h3 modulators
06/10/2010CA2745715A1 Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof
06/10/2010CA2745690A1 Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative
06/10/2010CA2745499A1 Peptide therapeutic conjugates and uses thereof
06/10/2010CA2745433A1 N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
06/10/2010CA2745420A1 N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
06/10/2010CA2745415A1 Methods for preventing or reducing carcinogenesis or oxidative stress
06/10/2010CA2745356A1 2h-chromene compound and derivative thereof
06/10/2010CA2745280A1 Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
06/10/2010CA2745073A1 Inhibition of hdac2 to promote memory
06/10/2010CA2745015A1 Pharmaceutical agent comprising quinolone compound
06/10/2010CA2744932A1 Nalmefene hydrochloride dihydrate
06/10/2010CA2744914A1 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives
06/10/2010CA2744489A1 Pyridazinone derivatives
06/10/2010CA2744300A1 1- (biphenyl-4-ylmethyl) imidazolidine-2, 4-dione derivatives and their use as cb2 receptor agonists
06/10/2010CA2744197A1 Synthesis and novel salt forms of (r)-3-((e)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
06/10/2010CA2742366A1 Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
06/09/2010EP2194121A1 Cell proliferation method, and pharmaceutical agent for repair and regeneration of tissue
06/09/2010EP2194056A1 Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use
06/09/2010EP2194044A1 Quinolone derivative
06/09/2010EP2193794A1 Use of eltoprazine for the treatment of L-Dopa-induced dyskinesia
06/09/2010EP2193793A1 Nerve cell death inhibitor
06/09/2010EP2193789A1 The application of 3, 5-dihydroxytoluene or derivatives thereof in the preparation of medicine and functional for treating or preventing depression.
06/09/2010EP2193788A1 Pharmaceutical compositions comprising colloidal silicon dioxide
06/09/2010EP2193133A2 Imidazolothiadiazoles for use as protein kinase inhibitors
06/09/2010EP2193129A1 6-pyrimidinyl-pyrimid-2-one derivative
06/09/2010EP2193119A1 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
06/09/2010EP2193117A1 Inhibitors of beta amyloid production
06/09/2010EP2192915A1 Therapeutic uses of peptides ysaypdsvpmms and wmnstgftkvcgappc
06/09/2010EP2192909A2 Modulation of tissue fatty acid composition of a host by human gut bacteria
06/09/2010EP2192834A1 Protein kinase c- inhibitors that protect against cellular injury and inflammation and promote astrocyte proliferation
06/09/2010EP1497273B1 Hydroxamic acid derivatives
06/09/2010EP1335907B1 Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor
06/09/2010EP1292308B1 Alpha,beta-unsaturated sulfones for treating proliferative disorders
06/09/2010EP1062226B1 High affinity nucleic acid ligands of the complement system c5 protein
06/09/2010CN1935010B Health food for intensifying body immunological competence and improving memory function, and its preparing method
06/09/2010CN1871000B Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pain
06/09/2010CN1662511B Pharmaceutical salts of reboxetine
06/09/2010CN101730706A Nmda and mc receptor antagonists exhibiting neuroprotective and memory enhancing activities
06/09/2010CN101730704A Stable salts of s-adenosylmethionine and process for the preparation thereof
06/09/2010CN101730696A 3-aza-bicyclo[3.3.0]octane compounds
06/09/2010CN101730691A Nitrogenated aromatic 6-membered ring derivative, and pharmaceutical agent comprising the same
06/09/2010CN101730684A sulfonyl-quinoline derivatives
06/09/2010CN101730678A Amino acid derivatives
06/09/2010CN101730565A Substituted phosphonates and their use in decreasing amyloid aggregates
06/09/2010CN101730530A titration of tapentadol
06/09/2010CN101724071A Single domain antibodies against TNFRl and methods of use therefor
06/09/2010CN101724003A Ginsenoside Rg1 containing impure notoginsenoside R1
06/09/2010CN101723955A Method for preparing olanzapine
06/09/2010CN101723954A Technique for preparing olanzapine
06/09/2010CN101723942A Method for preparing imide derivatives
06/09/2010CN101723941A '1,2,4' oxadiazoles as modulators of metabotropic glutamate receptor-5
1 ... 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 ... 1833